DGAP-News: Vita 34 AG / Key word(s): Quarter Results Vita 34 achieves further growth in market share and margin in the first quarter 09.05.2018 / 07:10 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Vita 34 achieves further growth in market share and margin in the first quarter - Sales revenue increased in the first quarter by 24.4% to EUR 5,076 thousand. - EBITDA continued to increase more than proportionately by 50.9% to EUR 1,067 thousand. - The EBITDA margin was 21.0%, thus in the range of the 20.0% target for the third quarter in succession. Leipzig, March 9, 2018 - Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), the second largest umbilical cord blood bank in Europe, has once again continued to build further on its market position in the first quarter of 2018. In the Company's core markets of Germany, Austria and Switzerland it has been able to gain further market share and assert its market leadership. Sales revenue in the first quarter increased compared to the previous year by 24.4% to EUR 5,076 thousand (Q1 2017: EUR 4,081 thousand). Growth in earnings before interest, taxes, depreciation and amortization (EBITDA) was once again higher, with an increase of 50.9% to EUR 1,067 thousand. As a result, the EBITDA margin was 21.0%, thus in the range of the 20.0% target for the third quarter in succession, and accordingly in line with the forecast for the year as a whole. In addition, the robust course of business has had a strong positive effect on the Company's financial situation. The cash flow from operating activities increased sharply to EUR 472 thousand (Q1 2017: EUR 18 thousand). "The significant increase in the number of stem cell deposits and the notable increase in market share since the acquisition last year clearly demonstrate how scalable our business model is," underlined Falk Neukirch, Vita 34 AG's Finance Director. The significant key figures for the Company's business development in the first quarter of 2018 were as follows: in EUR thousands Q1 2018 Q1 2017 Sales revenue 5,076 4,081 EBITDA 1,067 707 EBITDA margin (%) 21.0 17.3 EBIT 541 445 Net result for the period 308 280 Cash flow from operating activities 472 18 Liquid funds [31.03] 4,215 2,575 With respect to meeting the medium-term objectives set out in its "Vision 2021", the Company has made fundamental progress towards making the remaining part of the year 2018 a success. "In the coming months we will concentrate on building on the market leadership in Germany by further penetrating the DACH region (Germany, Austria, and German-speaking Switzerland) and, as a result, generate further sales growth," added Dr. Wolfgang Knirsch, Chairman of Vita 34's Management Board. "We want to increase the Company's profitability further by use of cost optimization projects." Following the successful acquisition in the previous year, Vita 34 is well prepared in structural and organizational terms to achieve further growth by organic means. The market for stem cell banks is currently in a consolidation phase, and it is part of the Company's strategy to play an active role in this process. The Management Board of Vita 34 AG will be available to qualified investors, analysts, and the press at 13.00 today during a public telephone conference in order to provide more detail on events in the first quarter of 2018. To register for the call, please contact the Investor Relations department by e-mail ( [email protected]). Contact: Ingo Middelmenne Investor Relations Vita 34 AG Telephone: +49 (0341) 48792 - 0 Mobile: +49 (0174) 9091190 E-mail: [email protected] Company Profile Vita 34 was founded in Leipzig in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider of cryo-preservation services, offers collection, logistics, preparation, and storage of stem cells from umbilical cord blood and tissue. Stem cells are a valuable base material for medical cell therapy and are kept alive at temperatures of minus 180 degrees Celsius, in order to be available for use in a treatment if needed. More than 200,000 customers from Germany and 28 other countries have already provided for their children's future with a stem cell deposit at Vita 34. --------------------------------------------------------------------------- 09.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Vita 34 AG Deutscher Platz 5a 04103 Leipzig Germany Phone: +49(0341)48792-40 Fax: +49(0341)48792-39 E-mail: [email protected] Internet: www.vita34.de ISIN: DE000A0BL849 WKN: A0BL84 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 683683 09.05.2018